Personalized Stem Cells (PSC), a human adipose-derived stem cell company, received FDA approval for an Investigational New Drug (IND) application for use of a person’s own stem cells to treat osteoarthritis. The first clinical trial will investigate use in the treatment of knee OA.
Future trials are planned for other orthopedic applications. PSC is working within FDA guidelines to provide alternatives to unregulated, in-clinic stem cell processing and unapproved regenerative therapies that have come under scrutiny by FDA, FTC and the Federation of State Medical Boards.
PSC was formed in 2018 to advance and legitimize human regenerative medicine. The company has licensed a portfolio of 70+ issued patents in the field.
Personalized Stem Cells (PSC), a human adipose-derived stem cell company, received FDA approval for an Investigational New Drug (IND) application for use of a person’s own stem cells to treat osteoarthritis. The first clinical trial will investigate use in the treatment of knee OA.
Future trials are planned for other orthopedic...
Personalized Stem Cells (PSC), a human adipose-derived stem cell company, received FDA approval for an Investigational New Drug (IND) application for use of a person’s own stem cells to treat osteoarthritis. The first clinical trial will investigate use in the treatment of knee OA.
Future trials are planned for other orthopedic applications. PSC is working within FDA guidelines to provide alternatives to unregulated, in-clinic stem cell processing and unapproved regenerative therapies that have come under scrutiny by FDA, FTC and the Federation of State Medical Boards.
PSC was formed in 2018 to advance and legitimize human regenerative medicine. The company has licensed a portfolio of 70+ issued patents in the field.
Copy to clipboard 
